Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Rubius Therapeutics

21/02/2023 15:18

* Rubius Therapeutics Inc  RUBY.OQ   RUBY.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 23 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Rubius Therapeutics
Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $1​, above​ its last closing price of $0.17.
​​​

This summary was machine generated February 21 at 15:18 GMT. 
All figures in US dollars  unless otherwise stated